The FDA has bestowed its priority review designation on Lynparza, setting it up for a billion-dollar opportunity—and a leg up on its PARP rivals.
Merck KGaA's EMD Serono wants to know what’s on the minds of multiple sclerosis patients and their loved ones.
With I-O drug development continually changing, an understanding of clinical biomarker testing is needed now more than ever.
The BioMarin-sponsored musical created by teens with hemophilia debuts today after a weekend of practice, camaraderie and education.
Merck is increasing its HPV vaccine production capacity, but it still won't be enough to meet the full demand in China, a company spokesperson said.
Could an FDA-approved digital pill that communicates with your mobile phone upend healthcare? A new Executive Insights explains.
With outcomes data showing Farxiga lowers hospitalizations for heart failure or CV deaths against placebo, AZ plans to file for a new FDA label.
The top 10 cancer drug makers of 2024.
Novo said it cracked down on the wholesaler through its local distributor Zuellig Pharma Korea, which terminated the alleged smuggler’s contract.
Coherus dialed up pressure on Amgen with its new Neulasta biosimilar approval, and now the company has unveiled its plan to steal market share.
England’s cost-effectiveness watchdogs aren’t convinced AZ and Merck’s PARP drug Lynparza is worth the cost in a bigger group of patients.
Big Pharma firms touted growth in China; Genentech sues ex-staffers and biosim company; Janssen licenses Yuhan's potential Tagrisso rival.
